CML: Renal function decline in TKI users

Key clinical point: There is a decline in renal function among patients with chronic myeloid leukaemia (CML) treated with tyrosine kinase inhibitors (TKIs).

Major finding: There was a significant reduction between the first and final recorded estimated glomerular filtration rate across all patients, declining by a mean of -12 mL/minute/1.73m² over the 10 years of measurement.

Study details: The data come from a retrospective analysis of 50 patients with CML treated with TKI therapy for at least 2 years.

,

Disclosures: No information on funding was available. The presenting author R Hinton declared no conflicts of interest. The second author S Arami reported relationships with various pharmaceutical companies.

Source: Hinton R et al. Poster. Abstract 053. BSH 2020. 2020 Nov 9-14.